In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions-Reference-Cited by-同舟云学术

In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions

Published:2018-04 Issue:4 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Murata Mika¹²,Kosai Kosuke¹,Yamauchi Shunsuke¹,Sasaki Daisuke¹,Kaku Norihito²^ORCID,Uno Naoki²,Morinaga Yoshitomo²,Hasegawa Hiroo¹,Miyazaki Taiga³,Izumikawa Koichi³,Mukae Hiroshi⁴,Yanagihara Katsunori²

Affiliation:

1. Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

2. Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

3. Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

4. Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Abstract

ABSTRACT Lascufloxacin showed potent activity against Streptococcus pneumoniae with a GyrA or ParC mutation (first-step mutant). The frequency of selecting resistant strains tended to be lower for lascufloxacin than for levofloxacin and garenoxacin after drug exposure in first-step mutants but was similar in the comparison between lascufloxacin and moxifloxacin. The increase in MIC was smaller for lascufloxacin than for levofloxacin, garenoxacin, and moxifloxacin when clinical strains with only ParC mutations were exposed to the corresponding drug.

Funder

Kyorin Pharmaceutical Co., Ltd.

Japan Agency for Medical Research and Development

Ministry of Health, Labour and Welfare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01971-17

Reference17 articles.

1. Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides

2. Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995

3. Molecular characterization of quinolone-insensitive Streptococcus pneumoniae isolates from Japanese patients

4. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.

5. In Vitro Activity of Garenoxacin against Streptococcus pneumoniae Mutants with Characterized Resistance Mechanisms

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular and phenotypic characterization of Streptococcus pneumoniae isolates in a Japanese tertiary care hospital;Frontiers in Cellular and Infection Microbiology;2024-07-22

2. Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial;Journal of Infection and Chemotherapy;2024-07

3. Effectiveness of Drip Infusion of Lascufloxacin, a Novel Fluoroquinolone Antibiotic, for Patients with Pneumonia Including Chronic Lung Disease Exacerbations and Lung Abscesses;Infection and Drug Resistance;2024-03

4. Bactericidal effect of lascufloxacin on HEp-2 cell-internalized group A Streptococcus;Journal of Infection and Chemotherapy;2023-04

5. Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol;Medicine;2023-02-22